FDA approves Emcitate as first treatment for MCT8 deficiency
The US Food and Drug Administration approved Emcitate tablets to treat peripheral thyrotoxicosis linked to MCT8 deficiency.
The US Food and Drug Administration approved Emcitate tablets to treat peripheral thyrotoxicosis linked to MCT8 deficiency.